Programme of the training course
Updated 2022 programme
Dr. Bernauer is a chemist by training and obtained her PhD degree in biochemical toxicology from the University of Wurzburg (Germany). During her doctorate she focussed on different aspects of chemical metabolism in animals and humans. She continued research at the German Federal Institute for Risk Assessment (BfR) and its predecessor institute with a focus on interspecies and interindividual variability of xenobiotic metabolism using cell culture and ex vivo models. From research, she turned into the regulatory area where she gained broad experience in risk assessment of chemicals within different regulatory contexts (e.g. industrial chemicals, cosmetics, workplace safety) and on a variety of toxicological endpoints. Currently her focus is on chemicals under REACH as deputy head of the Chemical Safety Unit. She has been involved in the development of conceptual frameworks for risk assessment, in test method developments, guideline development and human biomonitoring projects. Apart from being a regulatory toxicologist at BfR’s Chemical Safety Unit she has been appointed as a member of European Commissions Scientific Committee on Consumer Safety (SCCS) in 2009 and was involved in the risk assessment of a broad range of cosmetic ingredients including nanomaterials. Since 2016, she is chair of the SCCS working group on nanomaterials in cosmetic products. Dr. Bernauer is involved as a teacher in a variety of training programs on toxicology and safety assessment.
Prof. Paul Carmichael has worked in the Safety & Environmental Assurance Centre (SEAC) of Unilever in the UK since 2004, where he is responsible for the development and implementation of novel non-animal-based approaches for assuring human and environmental health; that is to say, how can consumer and environmental safety be assured without using and harming animals? He has over thirty years’ experience in toxicology and cancer research, largely in the academic arena, and prior to Unilever, he was a Senior Lecturer at Imperial College London in the Faculty of Medicine, where he taught pharmacology and toxicology and conducted research into advances in toxicology. A graduate of Surrey University with a B.Sc. in Biochemistry/Toxicology and a Ph.D. from King’s College London, he was a postdoctoral scientist at the Institute of Cancer Research (Royal Marsden Hospital) for seven years, exploring mechanisms of chemical genotoxicity and carcinogenicity. He currently has close academic links with Peking University in China (the School of Public Health) and is an Adjunct Assistant Professor of Pathology and Laboratory Medicine at Brown University in the USA. He has been an Endowed Professor at Wageningen University, Division of Toxicology in the Netherlands, since March 2020. He has published over one hundred research papers in peer-reviewed scientific journals and has served or serves on many external committees in the UK, US, EU and China. His passion is the advancement of new safety assessment approaches using the inspiration of ‘Toxicity Testing in the 21st Century’ – this can be termed ‘next generation risk assessments’ or NGRA.
After 45 years as university professor at the Faculties of Medicine of the Autonomous University of Madrid (1976-78), University of Freiburg (1987-88) and University of Valencia (1985-89) and holding the Chair of Biochemistry and Molecular Biology (1999-2021), and heading the Department (2016-2021), became Emeritus Professor at the Faculty of Medicine. Served as Research Director of the University Hospital La Fe in Valencia (2002-16), where continues as senior researcher at the Hospital Medical Research Center, leading the Unit of Experimental Hepatology.
Because of his achievements, in 1990, was given the International Award of the European Federation of Pharmaceutical Industries (Heidelberg). As scientific responsible of the “Analytical Unit” of the Medical Research Institute of Hospital La Fe he has fostered the application of MS-based metabolomics in the clinical world. He has been personally involved in developing metabolomic innovative strategies to investigate and anticipate the effects of new drugs on human liver cells, application of metabolomics to assess the quality of liver grafts prior to whole-organ liver transplantation, and to liver cell transplantation. He is actually involved in developing new strategies to monitor the degree of differentiation of hepatocytes generated from eSC, iPS or reprogrammed human cells. He pioneered the hepatocyte cell-transplantation program in Spain.
He has led over 50 research projects (among them 25 EU-Projects, being Coordinator in 2 of them), over 50 contracts with pharmaceutical industries and has authored 400 papers, including scientific articles, book chapters and several reviews, with an H-index of 60. Editor of the books: "In vitro alternatives to animal pharmacotoxicology" (Farmaindustria, Madrid 1992) and "In vitro methods in pharmaceutical research" (Academic Press, London 1997).
Qasim Chaudhry is currently a visiting Professor at University of Chester (UK). He has academic background in chemistry and biochemical toxicology, with longstanding expertise in health and environmental safety of food and other consumer products. His scientific career at the UK’s Food and Environment Research Agency (Fera) has encompassed assessing the health and environmental safety of chemicals and nanomaterials; in silico (computational) toxicology, natural products, development of immunodiagnostics, bioremediation, and modes of toxic action of chemicals. As an independent scientific Expert, Prof. Chaudhry provides his advice to the European Commission's Scientific Committee on Consumer Safety (SCCS); the European Food Safety Authority (EFSA); the UK's Food Standards Agency; and the UK’s Office for Product Safety and Standards.
Emanuela Corsini is a tenured full professor in toxicology at the School of Pharmacy at the Università degli Studi di Milano, Milan, Italy. As such, she organizes and teaches courses in the field of Toxicology at the School of Pharmacy and the School of Environmental Sciences, University of Milan. She has been active in training undergraduate and graduate students at her own university and has also developed and presented lectures for other academic institutions and professional societies. Her research focuses on the refinement of alternative in vitro tests for immunotoxicity, promoting the regulatory acceptance of alternative methods, and on the understanding the mechanism of action of immunotoxic/immunomodulatory compounds at the molecular level. Dr. Corsini has served on multiple ECVAM and ICCVAM Panels and Working groups to establish scientific confidence in alternative methods in immunotoxicology testing, performance standards for these novel assays and the development of integrated testing strategies for their use as part of comprehensive and predictive assessments. She has authored over 190 research publications in toxicology and related disciplines. She is active in numerous scientific and professional organizations and serves on several editorial boards of toxicology journals.
Biologist/Zoologist; Thesis in Genetic Toxicology (Technical University of Darmstadt 1987) Doctor in Biology/Zoology; Thesis in Immunotoxicology (Technical University of Darmstadt 1991) European Registered Toxicologist (since 2002)
Food Chemistry at the University of Kaiserslautern ; Thesis: Research on DNA- polymerase stops caused by selected N-nitrosoureas. Dr.rer.nat. at the University of Kaiserslautern, 1995 in the subject area: food chemistry and ecotoxicology with the thesis: N-nitroso-diethanolamine- analytic, study on inhibition and research on metabolic activation. European Registered Toxicologist (since 2005)
Carsten Goebel is currently leading the global product safety and regulatory affairs team at the Wella Company. This includes human safety leadership for the innovation program requiring toxicological research in the areas of skin sensitization and metabolism. He is a member of the German Society of Toxicology (DGPT)/EUROTOX and Immunology (DGfI) and a certified expert in both areas. He received his Ph.D. in Biology from the University of Düsseldorf, Germany, where his research focused on adverse immune effects of anti-rheumatic drugs including aromatic amines and the corresponding role of metabolic polymorphism. During his post-doc assignment, he was responsible for projects assessing the effect of xenobiotics on the immune system.
Currently, Carsten Goebel’s research is focused on better understanding the different exposure conditions of skin sensitization hazard and potency testing conditions (LLNA, HRIPT, diagnostic patch testing) compared to product use conditions with the goal to further refine current non-animal approaches for skin sensitization risk assessment. He has many peer-reviewed publications to his name and has published in journals including Regulatory Toxicology and Pharmacology, the British Journal of Dermatology and the Journal of Investigative Dermatology. Some of his most recent research established a new approach to quantitative risk assessment for skin sensitization of hair dye ingredients. This concept has been successfully applied to support the development of less sensitizing alternative hair dye molecules, such as 2-methoxymethyl-p-pehnylenediame, to improve the protection of hairdressers and hair color users from allergic contact dermatitis.
Prof. em. An Goossens became associated professor in 1990 and professor in 1996 at the Faculty of Medicine (KU Leuven), and was also, until 2011, guest professor at the Faculty of Pharmacy at the University of Antwerp. She was teaching dermato-cosmetics to pharmacists and medical students, specialization courses in contact dermatitis to dermatology residents and occupational dermatoses to occupational physicians. In October 2016, she retired as an “Emeritus professor with duties”, still giving courses to students in the Faculties of Medicine and Pharmaceutical Sciences (KU Leuven) until 2020. In 1982, she got a permanent position as a scientific co-worker in the Department of Dermatology (KU Leuven), where she became the head of the Contact allergy unit and has trained many national and international dermatology residents in this field. She also worked as an expert for the Federal Agency of Occupational Risks (FEDRIS) for patients with occupational dermatoses. She has been promotor of five doctoral theses and author or co-author of more than 400 articles in international peer reviewed scientific journals as well as of several book chapters. She was often invited to national and international congresses in the field of allergy and contact dermatitis. She is member and/or honorary member of the national and many international dermatological societies and member of the editorial board of scientific journals. She received several international awards, among which the International League of Dermatologic Societies (ILDS) Certificate of appreciation (2016).
Martine Grosber is head of the dermatology and allergology outpatient units of the University Hospital Brussels (UZ Brussel) since 2013. She studied medicine in Innsbruck (AT) and specialized in Dermatology in major university hospitals in Freiburg (D), Paris (F) and Munich (D). Her special interests are inflammatory skin diseases and allergies. She is member of the EAACI Drug Allergy Interest Group and the Belgian Contact and Environmental Dermatitis Group (BCEDG). She is a clinical tutor for dermatology at the Vrije Universiteit Brussels and full time supervisor for dermatology residents in the academic teaching hospital UZ Brussels. She organizes symposia on inflammatory skin diseases and allergies for general practitioners and dermatologists on a regular basis.
Petra Kern is a Principal Scientist/ Senior Toxicologist at Procter & Gamble (P&G) in Strombeek-Bever, Belgium. She joined P&G in 1999 and has been working in the Central Product Safety division of the Global Product Stewardship organization in Belgium and Beijing, China (2011-2016) within a global line function that reports into the head of safety within P&G in the USA. Her toxicology research specialty is in the area of Skin Allergy (Type IV Allergy) and Skin irritation and she is leading this research division at P&G. She is very active in the development of New Approach methodologies (NAM) in particular skin sensitization alternative methods and new generation skin allergy risk assessment approaches, AOPs, IATA etc. collaborating with industry, academics and regulators globally. Another area of expertise is regulatory toxicology, main focus REACH and CLP, including design of safety program and dossier preparation. She has been active as technical supervisor and coach for younger toxicology colleagues across the global safety department, including training on toxicology and risk assessment, study design, safety testing approaches and Technical External Relations issues. She has often presented the P&G research externally at scientific meetings or with regulators, and co-authored multiple (~100) peer-reviewed publications and book chapters. She is leading some (Cosmetic Europe (CE) and AISE) working groups and was/ is an active member of several industry association taskforces in Europe (CE, CEFIC, IFRA or ECETOC) as well as an expert member of OECD/ UH/GHS working groups, Petra Kern is a member of the European Society of Toxicology.
Dr Ouédraogo is passionate about research on alternative methods to animal testing. As a native of Burkina-Faso in west Africa, getting access to higher education is a great privilege. She strives to sharing this privilege with as many persons (who share the same passion) as possible; and learn from others as well. The journey started as a student in pharmacy where she started wet lab experiments in a laboratory of photobiology. Since then, she contributed to different initiatives (including European Framework projects) and successfully established and led number of collaborations for l’Oréal. As a scientific officer in the industry, she built a network with experts from different companies, sectors, SMEs and academic laboratories. She joined l’Oréal in 2003 to develop in vitro genotoxicity and cell transformation assays. In 2006, she took the lead of the genotoxicity and cancer group and transitioned in 2010 to managing teams of scientists working on different endpoints like skin sensitization, systemic toxicity, phototoxicity, genotoxicity. Since 2013, she leads research initiatives mainly with external partners on repeated dose systemic toxicity and genotoxicity. She is the representative of the company in different working groups at Cosmetics Europe, EU-ToxRisk, Riskhunt3R, OECD, HESI.
Dr Gerald Renner was born in Graz (Austria) in 1967. His basic scientific training is in engineering chemistry at the Technische Universität Graz, where he graduated in 1993. After that he specialised in biochemical engineering and worked for his PhD at the Technische Universität Graz, and the Ecole Polytechnique de Montréal. He finished his doctoral studies on the bacterial production of biodegradable plastics in 1996. After additional courses in animal cell culture techniques and immunology at the Université Libre de Bruxelles, he joined the Colipa (now Cosmetics Europe) Scientific department at the end of 1996. Since 2001 he is Cosmetic Europe’s Director of Technical Regulatory Affairs which includes since 2010 also the association s activities on international regulatory convergence.
After many years of leading the department of In Vitro Toxicology and Dermato-Cosmetology at the VUB in a successful way, Emeritus professor in Toxicology Vera Rogiers is actually still teaching dermato-cosmetics at the VUB and the University of Ghent. She also gives a limited number of lessons to the University of Namur and the Université Libre de Bruxelles. She yearly organizes international courses on Cosmetics and Risk Assessment. She is the Director of the Innovation Centre-3Rs (IC-3Rs) at the VUB and of the scientific Chair Mireille Aerens, both with focus on replacing experimental animals by novel technologies. At the EU level, she is co-chair of the Scientific Committee on Consumer Safety (SCCS) and member of the Mirror group of the European Partnership on Alternative Approaches to Animal Testing (EPAA). Her main research activity was many years situated in the development of in vitro models as an alternative to the use of experimental animals. Actual focus is on the differentiation of human skin-derived stem cells to functional hepatic cells and their application for drug discovery and the detection of drug-induced liver injury. She has been promoter of 33 doctoral theses, is author or co-author of >380 publications in international peer reviewed scientific journals and is editor of several scientific books. She is an often-invited speaker (>350) and participated in the organization of more than 60 international congresses. She has coordinated 2 EU research projects and was partner in several FP6, FP7 EU and Horizon 2020 research projects concerned with in vitro methodology development. Of the obtained scientific results, several patents have been filed. Throughout her carrier she received several international scientific awards for her pioneering role in in vitro Experimental Toxicology.
Since 2007, he is heading the global Toxicology department in Front End Innovation of Beiersdorf in Hamburg (Germany), focusing on development of alternative methods (NAMs) in the fields of Skin bioavailability and Sensitization, Mutagenicity, Irritation, ADME and digital toxicology. He is chairing Cosmetic Europe’s Task Force Skin Bioavailability/ADME in the Long Range Science Strategy Program since 2013. Dr. Schepky is a full member of the SOT, British Toxicology Society, the European Society of Toxicology in vitro as well as of the German Society of Pharmacology and Toxicology. He is author or co-author of multiple publications in international peer reviewed scientific journals and books with focus on alternatives to animal testing method development, performing case studies and proposing frameworks, including in vitro and digital toxicology approaches.
From 1989 till his early retirement in 2018 he was responsible as a senior toxicologist for the safety of global consumer goods (mainly cosmetic products) at Henkel AG & Co KGaA.
He worked in several committees and expert groups like the OECD, ECETOC, and Cosmetics Europe. During this time, he published about 100 articles and abstracts in international scientific journals and gave about 50 presentations at international congresses like the World Congresses on Alternative Methods, INVITOX, PPP, EUROTOX predominately on alternative methods. Since more than two decades he is giving lectures on toxicological topics at the German Universities of Düsseldorf, Witten, and Leipzig, in Frankfurt, and Brussels/Belgium and supervised toxicological master theses. Currently, he is a reviewer for several international scientific journals. Since 2019 he works as an expert in the German governmental development organization SES (Senior Expert Services).
Freddy obtained his Ph.D. degree in Science at the Free University of Brussels (Belgium) in 1995. After his post-doc, he joined Janssen (Belgium) as a Study Director for In Vitro, Genetic and Predictive toxicology. From 2003 to 2009, Freddy was the chairman of the Belgian Environmental Mutagen Society. During his career, he was responsible for the identification and validation of new in vitro test systems to assess the safety profile of compounds in early drug development. Today, he’s heading the Cell Health Assessment group of Janssen, who is responsible for high throughput liability screening and the development of a next generation in vitro predictive toxicology strategy.
Dr. Matthias Vey is a chemist by training from the Technical University of Darmstadt, Germany. After his studies and a short period of training as a perfumer he started in fragrance research and development for Marbert Cosmetics in Düsseldorf, Germany. He then became global regulatory affairs manager for Coty/Lancaster in Mainz, Germany.
In 2000 Dr. Vey joined IFRA. As Vice President Scientific Affairs, he is responsible for the fragrance industry's worldwide safe use program, known as the IFRA Standards. He also manages all of IFRA's science related committees and is involved in IFRA's advocacy activities. He is responsible for the management of the International Dialogue on the Evaluation of Allergens (IDEA), a multi-stakeholder initiative. He regularly presents at international meetings and conferences.
Based on the actual COVID-19 situation and ongoing travel restrictions, it’s been decided to organize the Safety Assessment of Cosmetics in the EU – 2022 online.
We’re handling online registration and online payment by credit card. Every registrant will automatically receive a PAID invoice.
The official language of the course is English.
No simultaneous translation will be provided.
The course material will be available from February 1, 2022 onwards. Access to the videos of the lectures (not webinars) will be granted until March 7, 2022.
The texts of the lectures and PDFs of the slides will be downloadable by the participants.
The registrations fees for the Online Safety Assessment of Cosmetics in the EU will be
Early Bird Registration fee (till 20 December 2021):
2500 euro per participant
Regular Registration fee (from 21 December 2021):
2900 euro per participant
Students: 600 euro per participant (Students are kindly requested to send their proof of being a student to Fabienne Van Bamis to receive their unique discount code).
The course fee, payable by credit card covers all lessons, course notes and participation to an online exam.
With OVER 20 YEARS OF EXPERIENCE in organizing the 'Safety Assessment of Cosmetics in the EU – Training Course', we can provide you with a sound and independent scientific counselling with regard to safety of cosmetic and their ingredients for the EU market*:
• development and/or improvement of your Product Information File (PIF)
Part A: cosmetic product safety information
Part B: cosmetic product safety assessment
• support and guidance in general cosmetic safety assessment
• advise on regulatory requirements (product adherence with EU legislation)
• ensuring that information about your cosmetic products is accurate and well presented
• INCI Ingredient labelling
• Cosmetovigilance – follow up assessment
* According to the Cosmetic Regulation EC N° 1223/2009 cosmetics circulating in Europe must demonstrate the evidence of their conformity with the stipulated requirements in the form of a Product Information File (PIF). A PIF is the mandatory compilation of technical documentation with regard to the description, the manufacturing methods, claims substantiation and a Cosmetic Product Safety Report.
Regrettably, no refunds will be made once the course has been payed and downloaded.